Summary
For families with a small number of cases of breast and/or ovarian cancer, limited data are available to predict the likelihood of genetic predisposition due to mutations in BRCA1 or BRCA2. In 104 families with three or more affected individuals (average 3.8) seeking counselling at family cancer clinics, mutation analysis was performed in the open reading frame of BRCA1 and BRCA2 by the protein truncation test and mutation-specific assays. In 31 of the 104 families tested, mutations were detected (30%). The majority of these mutations (25) occurred in BRCA1. Mutations were detected in 15 out of 25 families (60%) with both breast and ovarian cancer and in 16 out of 79 families (20%) with exclusively cases of breast cancer. Thus, an ovarian cancer case strongly predicted finding a mutation (P < 0.001). Within the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40 independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). Therefore, even small breast/ovarian cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should be referred for mutation screening.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Couch, F. J., DeShano, M. L., Blackwood, A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T. & Weber, B. L. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med, 336: 1409–1415.
Easton, D. F., Bishop, D. T., Ford, D. & Crockford, G. P. (1993). Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678–701.
Hogervorst, F. B. L., Cornelis, R. S., Bout, M., van Vliet, M., Oosterwijk, J. C., Olmer, R., Bakker, B., Klijn, J. G. M., Vasen, H. F. A., Meijers-Heijboer, H., Menko, F. H., Cornelisse, C. J., den Dunnen, J. T., Devilee, P. & van Ommen, G. J. B. (1995). Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet, 10: 208–212.
Krainer, M., Silva-Arrieta, S., FitzGerald, M. G., Shimada, A., Ishioka, C., Kanamaru, R., MacDonald, D. J., Unsal, H., Finkelstein, D. M., Bowcock, A., Isselbacher, K. J. & Haber, D. A. (1997). Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med, 336: 1416–1421.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C. h., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C. h., Tran, T. H., McClure, M., Frye, C. h., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C. h., Bogden, R., Dayannath, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A. & Skolnick, M. H. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266: 66–71.
Peelen, T., van Vliet, M., Petrij-Bosch, A., Mieremet, R., Szabo, C., van den Ouweland, A. W. M., Hogervorst, F., Brohet, R., Ligtenberg, M. J. L., Teugels, E., van der Luijt, R., van der Hout, A. H., Gille, J. J. P., Pals, G., Jedema, I., Olmer, R., van Leeuwen, I., Newman, B., Plandsoen, M., van der Est, M., Brink, G., Hageman, S., Arts, P. J. W., Bakker, M. M., Willems, H. W., van der Looij, E., Neyns, B., Bonduelle, M., Jansen, R., Oosterwijk, J. C., Sijmons, R., Smeets, H. J. M., van Asperen, C. J., Meijers-Heijboer, H., Klijn, J. G. M., de Greve, J., King, M. C., Menko, F. H., Brunner, H. G., Halley, D., van Ommen, G. J. B., Vasen, H. F. A., Cornelisse, C. J., van’t Veer, L. J., de Knijff, P., Bakker, E. & Devilee, P. (1997). A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet, 60: 1041–1049.
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., Meijers-Heijboer, H., Klijn, J. G. M., Vasen, H. F. A., Cornelisse, C. J., van’t Veer, L. J., Bakker, E., van Ommen, G. J. B. & Devilee, P. (1997). BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet, 17: 341–345.
Shattuck-Eidens, D., Oliphant, A., McClure, M., McBride, C., Gupte, J., Rubano, T., Pruss, D., Tavtigian, S. V., Teng, D. H. F., Adey, N., Staebell, M., Gumpper, K., Lundstrom, R., Hulick, M., Kelly, M., Holmen, J., Lingenfelter, B., Manley, S., Fujimura, F., Luce, M., Ward, B., Cannon-Albrigt, L., Steele, L., Offit, K., Gilewski, T., Norton, L., Brown, K., Schulz, C. h., Hampel, H., Schluger, A., Giulotto, E., Zoli, W., Ravaioli, A., Nevanlinna, H., Pyrhonen, S., Rowley, P., Loader, S., Osborne, M. P., Daly, M., Tepler, I., Weinstein, P. L., Scalia, J. L., Michaelson, R., Scott, R. J., Radice, P., Pierotti, M. A., Garber, J. E., Isaacs, C., Peshkin, B., Lippman, M. E., Dosik, M. H., Caligo, M. A., Greenstein, R. M., Pilarski, R., Weber, B., Burgemeister, R., Frank, T. S., Skolnick, M. H. & Thomas, A. (1997). BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA, 278: 1242–1250.
Szabo, C. I. & King, M. C. (1997). Population genetics of BRCA1 and BRCA2. Am J Hum Genet, 60: 1013–1020.
Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., Jammulapati, S., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J. F., Mitchell, J. T., McArthur-Morrison, J., Nguyen, K., Peng, Y., Samson, C., Schroeder, M., Snyder, S. C., Steele, L., Stringfellow, M., Stroup, C., Swedlund, B., Swensen, J., Teng, D., Thomas, A., Tran, T., Tran, T., Tranchant, M., Weaver-Feldhaus, J., Wong, A. K. C., Shizuya, H., Eyfjord, J. E., Cannon-Albright, L., Labrie, F., Skolnick, M. H., Weber, B., Kamb, A. & Goldgar, D. t. (1996). The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet, 12: 333–337.
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Avrill, D., Fields, P., Marshall, G., Narod, S., Lenoir, G. M., Lynch, H., Feunteun, J., Devilee, P., Cornlisse, C. J., Menko, F. H., Daly, P. A., Ormiston, W., McManus, R., Pye, C., Lewis, C. M., Cannon-Albright, L. A., Peto, J., Ponder, B. A. J., Skolnick, M. H., Easton, D. F., Goldgar, D. E. & Stratton, M. R. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science, 265: 2088–2090.
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., Barfoot, R., Hamoudi, R., Patel, S., Rice, C., Biggs, P., Hashim, Y., Smith, A., Connor, F., Arason, A., Gudmundsson, J., Ficenec, D., Kelsell, D., Ford, D., Tonin, P., Bishop, D. T., Spurr, N. K., Ponder, B. A. J., Eeles, R., Peto, J., Devilee, P., Cornelisse, C., Lynch, H., Narod, S., Lenoir, G., Egilsson, V., Bjork Barkadottir, R., Easton, D. F., Bentley, D. R., Futreal, P. A., Ashworth, A. & Stratton, M. R. (1995). Identification of the breast cancer susceptibility gene. BRCA2. Nature 378: 789–792.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ligtenberg, M., Hogervorst, F., Willems, H. et al. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer 79, 1475–1478 (1999). https://doi.org/10.1038/sj.bjc.6690235
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690235
Keywords
This article is cited by
-
Key steps for effective breast cancer prevention
Nature Reviews Cancer (2020)
-
The effects of radiotherapy for the treatment of contralateral breast cancer
Breast Cancer Research and Treatment (2007)
-
Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models
British Journal of Cancer (2006)
-
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients
European Journal of Human Genetics (2001)